Alan Hunter Shain

Alan Hunter Shain

Auto-generated profile, based on publicly available information

Alan Hunter Shain

Department of Dermatology, University of California, San Francisco, San Francisco, CA, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2017 in Science
Verified
Journal Article
Closed access
PDF file
KCKunitoshi Chiba
Kunitoshi Chiba
FLFranziska K. Lorbeer
Franziska K. Lorbeer
ASA. Hunter Shain
A. Hunter Shain
DMDavid T. McSwiggen
David T. McSwiggen
ESEva Schruf
Eva Schruf
DHDirk Hockemeyer
Dirk Hockemeyer
Two-step role for mutant TERT promoters: Telomeres preserve genomic stability by preventing chromosomal fusions. The recent discovery that human tumors harbor mutations in the promoter region of the telomerase gene ( TERT ) produced a flurry of research aimed at elucidating the role of these mutations in cancer development. Chiba et al. present data that reconcile many of the conflicting results reported to date (see the Perspective by Shay). In human melanoma samples and a fibroblast model, TERT promoter mutations acted in two steps. First, the mutations allowed cells to proliferate with short telomeres. This fueled genomic instability and up-regulation of telomerase expression, leading to uncontrolled cell proliferation. Science , this issue p. 1416 ; see also p. 1358

1 July 2018 in Cancer Cell
Verified
Journal Article
Closed access
ASA. Hunter Shain
A. Hunter Shain
NJNancy M. Joseph
Nancy M. Joseph
RYRichard Yu
Richard Yu
JBJamal Benhamida
Jamal Benhamida
SLShanshan Liu
Shanshan Liu
BBBoris C. Bastian
Boris C. Bastian

28 June 2019 in Nature Genetics
Verified
Journal Article
Open access
PDF file
ASA. Hunter Shain
A. Hunter Shain
MBMette M. Bagger
Mette M. Bagger
RYRichard Yu
Richard Yu
DCDarwin Chang
Darwin Chang
SLShanshan Liu
Shanshan Liu
JKJens F. Kiilgaard
Jens F. Kiilgaard
Uveal melanoma is a clinically distinct and particularly lethal subtype of melanoma originating from melanocytes in the eye. Here, we performed multi-region DNA sequencing of primary uveal melanomas and their matched metastases from 35 patients. We observed previously unknown driver mutations and established the order in which these and known driver mutations undergo selection. Metastases had genomic alterations distinct from their primary tumors; metastatic dissemination sometimes occurred early during the development of the primary tumor. Our study offers new insights into the genetics and evolution of this melanoma subtype, providing potential biomarkers for progression and therapy.

7 October 2020 in Nature
Verified
Journal Article
Closed access
PDF file
JTJessica Tang
Jessica Tang
EFEleanor Fewings
Eleanor Fewings
DCDarwin Chang
Darwin Chang
HZHanlin Zeng
Hanlin Zeng
SLShanshan Liu
Shanshan Liu
ASA. Hunter Shain
A. Hunter Shain

16 July 2021 in npj Genomic Medicine
Verified
Journal Article
Open access
PDF file
DCDarwin Chang
Darwin Chang
ASA. Hunter Shain
A. Hunter Shain
Cutaneous squamous cell carcinoma is a form of skin cancer originating from keratinocytes in the skin. It is the second most common type of cancer and is responsible for an estimated 8000 deaths per year in the United States. Compared to other cancer subtypes with similar incidences and death tolls, our understanding of the somatic mutations driving cutaneous squamous cell carcinoma is limited. The main challenge is that these tumors have high mutation burdens, primarily a consequence of UV-radiation-induced DNA damage from sunlight, making it difficult to distinguish driver mutations from passenger mutations. We overcame this challenge by performing a meta-analysis of publicly available sequencing data covering 105 tumors from 10 different studies. Moreover, we eliminated tumors with issues, such as low neoplastic cell content, and from the tumors that passed quality control, we utilized multiple strategies to reveal genes under selection. In total, we nominated 30 cancer genes. Among the more novel genes, mutations frequently affected EP300, PBRM1, USP28, and CHUK. Collectively, mutations in the NOTCH and p53 pathways were ubiquitous, and to a lesser extent, mutations affected genes in the Hippo pathway, genes in the Ras/MAPK/PI3K pathway, genes critical for cell-cycle checkpoint control, and genes encoding chromatin remodeling factors. Taken together, our study provides a catalog of driver genes in cutaneous squamous cell carcinoma, offering points of therapeutic intervention and insights into the biology of cutaneous squamous cell carcinoma.

26 January 2024 in Science Immunology
Verified
Journal Article
Closed access
DWDavid Wu
David Wu
AHAshley A. Hailer
Ashley A. Hailer
SWSijia Wang
Sijia Wang
MYMichelle Yuan
Michelle Yuan
JCJamie Chan
Jamie Chan
RCRaymond J. Cho
Raymond J. Cho
Psoriasis vulgaris and other chronic inflammatory diseases improve markedly with therapeutic blockade of interleukin-23 (IL-23) signaling, but the genetic mechanisms underlying clinical responses remain poorly understood. Using single-cell transcriptomics, we profiled immune cells isolated from lesional psoriatic skin before and during IL-23 blockade. In clinically responsive patients, a psoriatic transcriptional signature in skin-resident memory T cells was strongly attenuated. In contrast, poorly responsive patients were distinguished by persistent activation of IL-17–producing T (T17) cells, a mechanism distinct from alternative cytokine signaling or resistance isolated to epidermal keratinocytes. Even in IL-23 blockade–responsive patients, we detected a recurring set of recalcitrant, disease-specific transcriptional abnormalities. This irreversible immunological state may necessitate ongoing IL-23 inhibition. Spatial transcriptomic analyses also suggested that successful IL-23 blockade requires dampening of >90% of IL-17–induced response in lymphocyte-adjacent keratinocytes, an unexpectedly high threshold. Collectively, our data establish a patient-level paradigm for dissecting responses to immunomodulatory treatments.